Compare · CGC vs ONCR
CGC vs ONCR
Side-by-side comparison of Canopy Growth Corporation (CGC) and Oncorus Inc. (ONCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and ONCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 34.8x ONCR ($82.3M).
- CGC has hit the wire 9 times in the past 4 weeks while ONCR has been quiet.
- CGC has more recent analyst coverage (19 ratings vs 0 for ONCR).
- Company
- Canopy Growth Corporation
- Oncorus Inc.
- Price
- $0.71-3.03%
- $0.12-10.15%
- Market cap
- $2.86B
- $82.3M
- 1M return
- -23.35%
- -
- 1Y return
- -48.68%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 9
- 0
- Recent ratings
- 19
- 0
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Oncorus Inc.
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest CGC
- SEC Form DEFA14A filed by Canopy Growth Corporation
- SEC Form 8-K filed by Canopy Growth Corporation
- Canopy Growth’s Smiths Falls Facility Becomes Canada’s Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Director Yanofsky Theresa sold $13,828 worth of shares (14,920 units at $0.93), decreasing direct ownership by 10% to 131,495 units (SEC Form 4) to satisfy withholding obligation
- Director Lazzarato David Angelo sold $20,742 worth of shares (22,380 units at $0.93), decreasing direct ownership by 11% to 189,479 units (SEC Form 4) to satisfy tax liability
- Director Bayern Joseph sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 142,031 units (SEC Form 4) to cover withholding tax
- Director Atkins M Shan sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 143,421 units (SEC Form 4) (for withholding tax)
- Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany
- SEC Form DEFA14A filed by Canopy Growth Corporation
Latest ONCR
- SEC Form DEFA14A filed by Oncorus Inc.
- SEC Form 15-12G filed by Oncorus Inc.
- SEC Form DEFA14A filed by Oncorus Inc.
- Oncorus Inc. filed SEC Form 8-K: Leadership Update, Other Events, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form RW filed by Oncorus Inc.
- Oncorus Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update